The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma a Phase II Clinical Trial in China
Latest Information Update: 10 Apr 2024
At a glance
- Drugs ONCT 216 (Primary) ; Vincristine (Primary)
- Indications Ewing's sarcoma
- Focus Therapeutic Use
- Sponsors Shanghai Pharmaceuticals Holding
- 02 Apr 2024 Status changed from not yet recruiting to recruiting.
- 23 Nov 2023 Planned initiation date changed from 28 Oct 2023 to 28 Oct 2024.
- 23 Aug 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.